Vasopressin can increase coronary perfusion pressure during human cardiopulmonary resuscitation.

OBJECTIVES To determine the hemodynamic effect of vasopressin on coronary perfusion pressure (CPP) in prolonged human cardiac arrest. METHODS A prospective, open-label clinical trial of vasopressin during cardiac resuscitation was performed. Ten patients presenting in cardiac arrest initially received resuscitative measures by emergency physicians according to Advanced Cardiac Life Support (ACLS) guidelines. A central venous catheter for fluid and drug administration and a femoral artery catheter for measurement of CPP (aortic minus right atrial relaxation phase pressures) were placed. When each patient was deemed nonsalvageable, 1.0 mg epinephrine was given and CPP was measured for 5 minutes, followed by a dose of vasopressin (1.0 U/kg). CPP measurements were continued for another 5 minutes. RESULTS The mean duration of cardiac arrest (out-of-hospital interval plus duration of ED ACLS) was 39.6 +/- 16.5 min. There was no improvement in CPP after 1.0 mg of epinephrine. Vasopressin administration resulted in a significant increase of CPP in 4 of the 10 patients. Patients responding to vasopressin had a mean increase in CPP of 28.2 +/- 16.4 mm Hg (range: 10-51.5), with these peak increases occurring at 15 seconds to 4 minutes after administration. The increases in the vasopressin levels after administration did not differ between the responders and nonresponders. CONCLUSIONS In this human model of prolonged cardiac arrest, 40% of the patients receiving vasopressin had a significant increase in CPP. This pilot study suggests that investigation of earlier use of vasopressin as a therapeutic alternative in the treatment of cardiac arrest is warranted.

[1]  K. Lindner,et al.  Cardiovascular function during the postresuscitation phase after cardiac arrest in pigs: a comparison of epinephrine versus vasopressin. , 1996, Critical care medicine.

[2]  K. Lindner,et al.  Vasopressin Administration in Refractory Cardiac Arrest , 1996, Annals of Internal Medicine.

[3]  Wanchun Tang,et al.  Epinephrine increases the severity of postresuscitation myocardial dysfunction. , 1995, Circulation.

[4]  M. Georgieff,et al.  Vasopressin Improves Vital Organ Blood Flow During Closed-Chest Cardiopulmonary Resuscitation in Pigs , 1995 .

[5]  N. Buderer,et al.  The effect of the total cumulative epinephrine dose administered during human CPR on hemodynamic, oxygen transport, and utilization variables in the postresuscitation period. , 1994, Chest.

[6]  C. Otto,et al.  High‐dose epinephrine results in greater early mortality after resuscitation from prolonged cardiac arrest in pigs: A prospective, randomized study , 1994, Critical care medicine.

[7]  M. Goetting,et al.  High atrial natriuretic peptide concentrations blunt the pressor response during cardiopulmonary resuscitation in humans , 1994, Critical care medicine.

[8]  N. Paradis,et al.  The effect of global ischemia and reperfusion on the plasma levels of vasoactive peptides. The neuroendocrine response to cardiac arrest and resuscitation. , 1993, Resuscitation.

[9]  K. Lindner,et al.  Effect of vasopressin on hemodynamic variables, organ blood flow, and acid-base status in a pig model of cardiopulmonary resuscitation. , 1993, Anesthesia and analgesia.

[10]  S. Stoev,et al.  Receptor‐Specific Antagonists of Vasopressin and Oxytocin , 1993 .

[11]  M. Thibonnier,et al.  Cytoplasmic and nuclear signaling pathways of V1-vascular vasopressin receptors , 1993, Regulatory Peptides.

[12]  H. Smithline,et al.  Venous hyperoxia after cardiac arrest. Characterization of a defect in systemic oxygen utilization. , 1992, Chest.

[13]  C. Barton,et al.  A randomized clinical trial of high-dose epinephrine and norepinephrine vs standard-dose epinephrine in prehospital cardiac arrest. , 1992, JAMA.

[14]  P. Pepe,et al.  A comparison of standard-dose and high-dose epinephrine in cardiac arrest outside the hospital. The Multicenter High-Dose Epinephrine Study Group. , 1992, The New England journal of medicine.

[15]  I. Stiell,et al.  High-dose epinephrine in adult cardiac arrest. , 1992, The New England journal of medicine.

[16]  M. Georgieff,et al.  Stress hormone response during and after cardiopulmonary resuscitation. , 1992, Anesthesiology.

[17]  M. Lapiński,et al.  Effect of vasopressin and V1 receptors blockade on hypotensive action of ANP in normotensive (WKY) and spontaneously hypertensive rats. , 1992, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[18]  T. J. Appleton,et al.  The effect of standard- and high-dose epinephrine on coronary perfusion pressure during prolonged cardiopulmonary resuscitation. , 1991, JAMA.

[19]  K. Lindner,et al.  Comparison of different doses of epinephrine on myocardial perfusion and resuscitation success during cardiopulmonary resuscitation in a pig model. , 1991, The American journal of emergency medicine.

[20]  T. Totoki,et al.  A median epidural septum is not a common cause of unilateral epidural blockade. , 1990, Anesthesia and analgesia.

[21]  K. Lindner,et al.  Epinephrine and norepinephrine in cardiopulmonary resuscitation. Effects on myocardial oxygen delivery and consumption. , 1990, Chest.

[22]  T. J. Appleton,et al.  Coronary perfusion pressure and the return of spontaneous circulation in human cardiopulmonary resuscitation. , 1990, JAMA.

[23]  B. Walker,et al.  Direct cardiac effects of vasopressin: role of V1- and V2-vasopressinergic receptors. , 1988, The American journal of physiology.

[24]  J. Lindenfeld,et al.  Failure of epinephrine to improve the balance between myocardial oxygen supply and demand during closed-chest resuscitation in dogs. , 1988, Circulation.

[25]  P. Safar,et al.  Deferred consent. A new approach for resuscitation research on comatose patients. , 1986, JAMA.

[26]  P. Cryer,et al.  External and internal standards in the single-isotope derivative (radioenzymatic) measurement of plasma norepinephrine and epinephrine. , 1985, The Journal of laboratory and clinical medicine.

[27]  J. Liard,et al.  Vasopressin in cardiovascular control: role of circulating vasopressin. , 1984, Clinical science.

[28]  J. T. Shepherd,et al.  Vasopressin Causes Endothelium‐Dependent Relaxations of the Canine Basilar Artery , 1984, Circulation research.

[29]  Schrier Rw,et al.  Effect of calcium membrane blockers on in vivo vasoconstrictor properties of norepinephrine, angiotensin II and vasopressin. , 1984 .

[30]  R. Schrier,et al.  Interrelationship between subpressor effects of vasopressin and other vasoactive hormones in the rat. , 1984, Mineral and electrolyte metabolism.

[31]  M. Faure,et al.  Vasopressin and angiotensin II receptors in rat aortic smooth muscle cells in culture. , 1983, The American journal of physiology.

[32]  A. F. Muller,et al.  Reversible ischemic colitis after intravenous vasopressin therapy. , 1982, JAMA.

[33]  R. Michell,et al.  Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin. , 1979, Biochemical Society transactions.

[34]  G. Buckberg,et al.  Optimizing myocardial supply/demand balance with alpha-adrenergic drugs during cardiopulmonary resuscitation. , 1978, The Journal of thoracic and cardiovascular surgery.

[35]  J. C. Kerr,et al.  Vasopressin and blood flow to the canine small intestine. , 1978, The Journal of surgical research.